ES2126331T3 - Conjugados de bdnf y nt-3 con un polimero soluble en agua. - Google Patents

Conjugados de bdnf y nt-3 con un polimero soluble en agua.

Info

Publication number
ES2126331T3
ES2126331T3 ES95939123T ES95939123T ES2126331T3 ES 2126331 T3 ES2126331 T3 ES 2126331T3 ES 95939123 T ES95939123 T ES 95939123T ES 95939123 T ES95939123 T ES 95939123T ES 2126331 T3 ES2126331 T3 ES 2126331T3
Authority
ES
Spain
Prior art keywords
water soluble
soluble polymer
bdnf
conjugates
polypeptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95939123T
Other languages
English (en)
Inventor
Olaf F Kinstler
Qiao Yan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of ES2126331T3 publication Critical patent/ES2126331T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/839—Nerves; brain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Treatment Of Sludge (AREA)
  • Treatment Of Water By Ion Exchange (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Detergent Compositions (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)

Abstract

SE HAN PREPARADO DERIVADOS DE FACTORES NEUROTROFICOS BDNF Y NT3 MEDIANTE INCORPORACION DE ESTOS POLIPEPTIDOS A UN POLIMERO SOLUBLE EN AGUA, POR EJEMPLO, POLIETILENGLICOL.
ES95939123T 1994-11-14 1995-11-13 Conjugados de bdnf y nt-3 con un polimero soluble en agua. Expired - Lifetime ES2126331T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/340,131 US5770577A (en) 1994-11-14 1994-11-14 BDNF and NT-3 polypeptides selectively linked to polyethylene glycol

Publications (1)

Publication Number Publication Date
ES2126331T3 true ES2126331T3 (es) 1999-03-16

Family

ID=23332020

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95939123T Expired - Lifetime ES2126331T3 (es) 1994-11-14 1995-11-13 Conjugados de bdnf y nt-3 con un polimero soluble en agua.

Country Status (22)

Country Link
US (1) US5770577A (es)
EP (1) EP0792288B1 (es)
JP (1) JPH10508853A (es)
KR (1) KR100253762B1 (es)
CN (1) CN1173183A (es)
AT (1) ATE175973T1 (es)
AU (1) AU694589B2 (es)
CA (1) CA2204640C (es)
CZ (1) CZ137597A3 (es)
DE (1) DE69507507T2 (es)
DK (1) DK0792288T3 (es)
ES (1) ES2126331T3 (es)
GR (1) GR3029790T3 (es)
HU (1) HUT77747A (es)
IL (1) IL115965A (es)
MX (1) MX9703362A (es)
NO (1) NO972176L (es)
NZ (1) NZ296452A (es)
RU (1) RU2136694C1 (es)
SK (1) SK283083B6 (es)
WO (1) WO1996015146A1 (es)
ZA (1) ZA959653B (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
JPH10212241A (ja) * 1996-05-27 1998-08-11 Sumitomo Pharmaceut Co Ltd Ｂｄｎｆを安定に含有する製剤
NZ333650A (en) 1996-07-19 2000-02-28 Amgen Inc Analogs of cationic proteins like NT-3 (neurotrophin-3) and BDNF (brain derived neurotrophic factor) that are circulated more readily due to a lower isoelectric point and a lower protein charge relative to the native protein
WO2000024415A2 (en) * 1998-10-28 2000-05-04 Cornell Research Foundation, Inc. Methods for regulating angiogenesis and vascular integrity using trk receptor ligands
US6656474B1 (en) * 1999-01-15 2003-12-02 Regeneron Pharmaceuticals, Inc. Methods of using a neurotrophin and its analogues for the treatment of gastrointestinal hypomotility disorders
RU2290411C2 (ru) * 2000-01-10 2006-12-27 Максиджен Холдингз Лтд Конъюгаты g-csf
US6800607B2 (en) * 2000-02-29 2004-10-05 Ltt Bio-Pharma Co., Ltd. Modified BDNF
US7514239B2 (en) * 2000-03-28 2009-04-07 Amgen Inc. Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptides and heterodimers thereof
US6586398B1 (en) 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
JP4259868B2 (ja) * 2001-02-01 2009-04-30 バイオジェン・アイデック・エムエイ・インコーポレイテッド ニューブラスチンのポリマー結合体および同様の使用方法。
US7442370B2 (en) * 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
JP4279554B2 (ja) 2001-02-19 2009-06-17 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｔ細胞エピトープの識別方法および低減された免疫原性を有する分子の製造方法
EP1234583A1 (en) * 2001-02-23 2002-08-28 F. Hoffmann-La Roche Ag PEG-conjugates of HGF-NK4
US7276580B2 (en) * 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
RU2307126C2 (ru) * 2001-07-11 2007-09-27 Максиджен Холдингз Лтд. Конъюгаты g-csf
ATE344289T1 (de) * 2002-07-24 2006-11-15 Hoffmann La Roche Polyethylenglykol-aldehydderivate
JP4571776B2 (ja) * 2002-11-05 2010-10-27 Ｊｘ日鉱日石エネルギー株式会社 潤滑油組成物
RS20050501A (sr) * 2002-12-26 2007-08-03 Mountain View Pharmaceuticals Inc., Polimerni konjugati citokina,hemokina,faktora rasta, polipeptidnih hormona i njihovih antagonista sa očuvanom aktivnošću vezivanja receptora
GEP20084486B (en) * 2002-12-26 2008-09-25 Mountain View Pharmaceuticals Polymer conjugates of interferon-beta with enhanced biological potency
JP4742025B2 (ja) * 2003-01-31 2011-08-10 バイオジェン・アイデック・エムエイ・インコーポレイテッド 変異ニューブラスチンのポリマー結合体
PL1606409T3 (pl) 2003-03-19 2011-02-28 Biogen Ma Inc Białko wiążące receptor Nogo
EP1897552B1 (en) 2003-04-18 2009-06-17 Biogen Idec MA Inc. Polymer-conjugated glycosylated neublastin
BRPI0506793A (pt) * 2004-02-20 2007-05-22 Rinat Neuroscience Corp métodos de tratamento de obesidade ou diabetes com o uso de nt-4/5
PT1776136E (pt) 2004-06-24 2012-12-05 Biogen Idec Inc Tratamento de estados que envolvem desmielinização
CN101043899B (zh) 2004-08-19 2011-03-30 比奥根艾迪克Ma公司 重折叠转化型生长因子beta家族蛋白
DK1786454T3 (da) * 2004-08-19 2010-09-06 Biogen Idec Inc Neublastinvarianter
MX2007015292A (es) 2005-06-06 2008-02-21 Wyeth Corp Anticuerpos monoclonales anti-trkb y sus usos.
SI1904104T1 (sl) 2005-07-08 2013-12-31 Biogen Idec Ma Inc. Protitelesa SP35 in njihova uporaba
ITRM20050447A1 (it) * 2005-08-19 2007-02-20 Anabasis S R L Uso del nerve growth factor in collirio nella terapia di patologie del sistema nervoso centrale, quali la malattia di alzheimer e il morbo di parkinson.
AU2007210862A1 (en) * 2006-02-02 2007-08-09 Rinat Neuroscience Corp. Methods for treating unwanted weight loss or eating disorders by administering a trkB agonist
JP2009525319A (ja) * 2006-02-02 2009-07-09 ライナット ニューロサイエンス コーポレイション ｔｒｋＢアンタゴニストを投与することにより肥満を治療する方法
TWI501774B (zh) 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
US20100056440A1 (en) * 2006-03-01 2010-03-04 Biogen Idec Ma Inc. Compositions and methods for administering gdnf ligand family proteins
WO2007133811A2 (en) * 2006-05-15 2007-11-22 Viral Logic Systems Technology Corp. Cd47 related compositions and methods for treating immunological diseases and disorders
US8377448B2 (en) * 2006-05-15 2013-02-19 The Board Of Trustees Of The Leland Standford Junior University CD47 related compositions and methods for treating immunological diseases and disorders
CA2672750A1 (en) * 2006-12-20 2008-07-03 Rinat Neuroscience Corporation Trkb agonists for treating autoimmune disorders
TWI445544B (zh) 2007-05-01 2014-07-21 Biogen Idec Inc 增進血管形成之組合物及方法
US20110135648A1 (en) * 2007-08-08 2011-06-09 Biogen Idec Ma Inc. Anti-neublastin antibodies and uses thereof
CA2701189C (en) * 2007-10-11 2017-05-16 Biogen Idec Ma Inc. Methods for treating pressure induced optic neuropathy, preventing neuronal degeneration and promoting neuronal cell survival via administration of lingo-1 antagonists and trkb agonists
WO2009061500A1 (en) * 2007-11-08 2009-05-14 Biogen Idec Ma Inc. Use of lingo-4 antagonists in the treatment of conditions involving demyelination
EP2315779A2 (en) 2008-07-09 2011-05-04 Biogen Idec MA Inc. Compositions comprising antibodies to lingo or fragments thereof
EP2588490B1 (en) 2010-07-02 2017-02-22 Angiochem Inc. Short and d-amino acid-containing polypeptides for therapeutic conjugates and uses thereof
US9796780B2 (en) 2012-05-14 2017-10-24 Biogen Ma Inc. LINGO-2 antagonists for treatment of conditions involving motor neurons
CN102964442B (zh) * 2012-11-19 2015-04-29 未名生物医药有限公司 一种聚乙二醇同神经生长因子结合物的制备方法
WO2016112270A1 (en) 2015-01-08 2016-07-14 Biogen Ma Inc. Lingo-1 antagonists and uses for treatment of demyelinating disorders
CN116440252A (zh) * 2020-06-16 2023-07-18 温州医科大学附属第二医院（温州医科大学附属育英儿童医院） 神经营养因子3在制备提高睾丸中睾酮含量的药物中的应用
CN115025723A (zh) * 2022-05-10 2022-09-09 吉林大学 经神经生长因子及多巴胺改良的peg-plga微球

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) * 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US5169762A (en) * 1983-03-03 1992-12-08 Genentech, Inc. Human nerve growth factor by recombinant technology
DE3572982D1 (en) * 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
GB8430252D0 (en) * 1984-11-30 1985-01-09 Beecham Group Plc Compounds
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
CA1340810C (en) * 1988-03-31 1999-11-02 Motoo Yamasaki Polypeptide derivatives of human granulocyte colony stimulating factor
EP0401384B1 (en) * 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
IL95511A (en) * 1989-08-30 2000-10-31 Max Planck Gesellschaft Neurotrophin-3 a novel neurotrophic factor related to nerve growth and brain derived neurotrophic factor
US5229500A (en) * 1989-08-30 1993-07-20 Regeneron Pharmaceuticals, Inc. Brain derived neurotrophic factor
US5180820A (en) * 1989-08-30 1993-01-19 Barde Yves Alain Brain-derived neurotrophic factor
US5182107A (en) * 1989-09-07 1993-01-26 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
JPH04218000A (ja) * 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド
IE912365A1 (en) * 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
CA2092567C (en) * 1990-09-25 2007-07-03 Arnon Rosenthal Nt-4 neurotrophic factor
US5252714A (en) * 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5389529A (en) * 1991-06-12 1995-02-14 Regeneron Pharmaceuticals, Inc. Modified lamβ signal sequence and processes for producing recombinant neurotrophins
NZ244778A (en) * 1991-10-21 1994-03-25 Ortho Pharma Corp Peg imidates and protein derivatives thereof
US5260308A (en) * 1991-11-06 1993-11-09 Mayo Foundation For Medical Education And Research Method to increase permeability of the blood-nerve/brain barriers to proteins
US5468872A (en) * 1993-09-16 1995-11-21 Cephalon, Inc. K-252a functional derivatives potentiate neurotrophin-3 for the treatment of neurological disorders

Also Published As

Publication number Publication date
AU694589B2 (en) 1998-07-23
ATE175973T1 (de) 1999-02-15
DK0792288T3 (da) 1999-09-13
ZA959653B (en) 1997-08-26
KR100253762B1 (ko) 2000-05-01
AU4107196A (en) 1996-06-06
CA2204640C (en) 2001-01-09
CA2204640A1 (en) 1996-05-23
IL115965A0 (en) 1996-01-31
DE69507507D1 (de) 1999-03-04
WO1996015146A1 (en) 1996-05-23
NO972176L (no) 1997-07-14
EP0792288A1 (en) 1997-09-03
CZ137597A3 (cs) 1998-10-14
NO972176D0 (no) 1997-05-12
DE69507507T2 (de) 1999-05-27
NZ296452A (en) 1999-01-28
CN1173183A (zh) 1998-02-11
US5770577A (en) 1998-06-23
EP0792288B1 (en) 1999-01-20
MX9703362A (es) 1997-08-30
SK57197A3 (en) 1999-02-11
RU2136694C1 (ru) 1999-09-10
SK283083B6 (sk) 2003-02-04
IL115965A (en) 2001-01-28
JPH10508853A (ja) 1998-09-02
HUT77747A (hu) 1998-07-28
GR3029790T3 (en) 1999-06-30

Similar Documents

Publication Publication Date Title
ZA959653B (en) Derivatives of BDNF and NT-3.
FI941434L (fi) Polymeerisäiliöitä, joilla on sulkuominaisuuksia
FI931278A0 (fi) Polymerer, som innehaoller sulfogrupper
DE69726229D1 (de) Prothese mit Flansch
FI961253A0 (fi) Virtsaputkeen tiivistyvä peitetulppa
DE69617500D1 (de) Totale Gelenkprothese mit beweglichem Lager
MY125467A (en) Olanzapine dihydrate d
BR9601242A (pt) Composição de vidro de cor bronze e folha de vidro da mesma
DE69008954D1 (de) Einsetzbares künstliches Schliessmuskelsystem.
FI940738A0 (fi) Elektroneja johtavia molekyylivalmisteita
BR9711949B1 (pt) sistema de telecomunicações tendo a faculdade de relocalização de número de assinante, e, processo de operar um sistema de telecomunicações.
DE68912018D1 (de) UV-härtbare Polymerzusammensetzung.
DE69707275D1 (de) Dichter elektrochemischer generator mit endschutzschalter
TR199501725A2 (tr) Sizdirmazlik düzeni.
EP0561916A4 (en) Membrane made from multiblock polymer
EP0621044A3 (en) Collagen membrane.
BR9503330A (pt) Recipiente dotado de um colo aberto anular
DE69121461D1 (de) Lichtempfindliches, wärmebeständiges Polymer mit Hydroxyphenylgruppen
ITTO940416A0 (it) Cariche pigmentati per composizioni polimeriche.
DE3862372D1 (de) Polyphenylenaether, polyoctenylen und polyethylen enthaltende polymermischung.
FR2706285B1 (fr) Prothèse anti-luxation.
FI962120L (fi) Estramustiiniformulaatiot, joilla on parannetut farmaseuttiset ominaisuudet
AU4435089A (en) Preparation of poly(aryl ether/thioether)-polyester block copolymers
EP0621623A3 (en) Double-based low pressure discharge lamp.
ES1026166Y (es) Baliza de señalizacion perfeccionada.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 792288

Country of ref document: ES